

Preclinical study supporting IND clearance for phase 2 clinical trial of HBPB1-007 peptide eye-drop therapy in geographic atrophy secondary to age-related macular degeneration



OPHTHALMOLOGY	Preclinical
Product Type	rProtein
Indication	Geographic Atrophy secondary to dry Age-related Macular Degeneration
Target	TIR domain of Toll-like receptor(TLR) and its adaptor proteins
MoA(Mechanism of Action)	Protect RPE cells by suppressing inflammation through inhibiting the interaction between TIR domains of Toll-like receptor (TLR) and its adaptor proteins.
Competitiveness	• Differentiated mechanism of action targeting TLR4 signaling to suppress inflammation, offering improved clinical benefits over current therapies. • Superior patient compliance by replacing invasive IVT therapies with a user-friendly eye drop formulation.
Development Stage	Preclinical
Route of Administration	Ocular instillation (Eye drop)

Any unauthorized distribution or reproduction of this material is strictly prohibited.